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Impact: The optimal range of circulating vitamin D for prostate cancer prevention may be narrow. Supplementation of men with adequate levels may be harmful.
Introduction
The role of vitamin D in prostate cancer risk remains controversial. There is a large body of evidence based on in-vitro, animal experimental and ecological studies, which suggests that inadequate vitamin D could increase prostate cancer risk (1) ; however the results of longitudinal studies based on pre-diagnostic serum concentrations of vitamin D (25-hydroxy vitamin D) are mixed. With the exception of small studies (n<200 cases), no longitudinal study has reported a significant inverse association of vitamin D with prostate cancer; most have reported no association of serum vitamin D with risk (2-7) and others have reported statistically-significant associations that are U-shaped (8) , inverted U-shaped (9, 10) and positive (11) (12) (13) . The reasons for inconsistency across studies are unclear.
Here we give results on vitamin D and prostate cancer risk from the Selenium and Vitamin E Cancer Prevention Trial. (SELECT) This is one of the largest studies to date examining blood vitamin D and prostate cancer incidence, with 1,731 total and 502 high-grade (Gleason [7] [8] [9] [10] cases. There are also a sufficient number of cases (n=250) among African-American men to support a stratified analysis, which is of considerable interest because, compared to Caucasian men, African American men have both a higher risk of prostate cancer (14) and lower blood vitamin D concentrations (15) . Results of this study can help resolve the question of whether or not circulating concentrations of vitamin D are associated with prostate cancer risk.
Materials and Methods
Data and blood samples for this study are from the Selenium and Vitamin E Cancer Prevention Trial (SELECT), which was a randomized, placebo-controlled trial that tested whether selenium and vitamin E, either alone or combined, reduced prostate cancer risk (16) .
Briefly, in 427 participating sites across the United States, Canada, and Puerto Rico, men ≥50 years (African-American) or ≥55 years (all other men) of age, who had no history of prostate cancer, and who had a serum Prostate Specific Antigen (PSA) of ≤4ng/ml and non-suspicious digital rectal exam (DRE) were eligible to participate. Between July 2001 and May 2004, 35,533 men were block-randomized by study site to one of 4 groups: selenium + vitamin E; vitamin E + placebo; selenium + placebo; or placebo + placebo. On September 15, 2008 , the Data and Safety Monitoring Committee recommended the discontinuation of the trial supplements due to no observed evidence of a protective effect and no likelihood of an effect given current rates of cancer in each arm. All men provided written informed consent and study procedures were approved by local institutional review boards for each participating study center.
The present study is a case-cohort design nested within SELECT. Cases included in these analyses were men with baseline blood samples available for analysis who were diagnosed with incident, primary prostate cancers before July 31, 2009. Most cases (95.0%) were detected by PSA and/or DRE screening, which was suggested annually but not required. At each annual visit, participants reported screening procedures during the preceding year and, at each quarterly of 1731) were reviewed centrally for pathological confirmation and grading using the Gleason system. For 43 cases from whom slides were not available, Gleason scores were abstracted from local pathology reports. For the main analyses, high-grade tumors were defined as Gleason Scores 7-10 and more conservatively as Gleason Scores 8-10, and low-grade tumors were
Gleason Scores 2-6. Grade was unknown for 215 cases.
A subcohort representative of SELECT participants was created a priori as the comparison group for this and other biomarker studies, using the following approach. Men randomized into the study who had baseline blood samples available were stratified into 9 age/race cohorts: <55 for African Americans, and 55-59, 60-64, 65-69, ≥70 years for both African Americans and others. For each case, men were selected for the subcohort at random from the same age/race group, using a ratio of 1:3 for African Americans and 1:1.5 for others.
There were 3,203 men in the subcohort, of whom 201 were also cases.
Data on demographic and health-related characteristics were collected at baseline by selfadministered questionnaire. Study staff measured height and weight, which were used to calculate body mass index (BMI; kg/m 2 ). Venous blood samples, collected after a minimum 4 hour fast, were collected at baseline, refrigerated and shipped overnight to the specimen repository where the samples were centrifuged, aliquoted, and stored at -70 o C until analysis.
Vitamin D (25-OH) concentration in plasma was measured using the LIAISON® 25 OH Vitamin D TOTAL Assay (DiaSorin Inc., Stillwater, MN), which is a chemiluminescent immunoassay, following manufacturer's instructions. The limit of quantitation of this assay was 4 ng/mL. Each batch of samples was bracketed by both a low (pooled plasma) and high (BioRad 6 Liquichek Level 3) quality control sample; their inter-batch coefficients of variation (CVs) were 12.1% and 6.9%, respectively. Starting in 2005 and continuing annually through 2009, samples from cases and the subcohort members selected due to each case were analyzed in the same batch, and laboratory personnel were blinded to the status of the samples. Two or three separate aliquots from 376 men were analyzed in batches completed in different years; from these samples the weighted average of the coefficients of variation for vitamin D was 15.5%, and there was a small assay drift of approximately -3 nmol/L per year.
Cox proportional hazards models were used to estimate hazard ratios (HR) and 95% CI for the association between plasma vitamin D and risk of prostate cancer. Separate models were fit for total, Gleason 2-6 and Gleason 7-10 cancers. Models for Gleason 8-10 cancer were completed only for the analyses not stratified by race, due to small number of these cases. Cases not occurring in the subcohort enter the proportional hazards model just prior to diagnosis and remain in the model until diagnosis. Non-cases in the subcohort enter the model at randomization and continue until they are censored. Cases in the subcohort appear in the model twice: once treated as non-cases in the subcohort (entering at randomization, censored just prior to diagnosis), and once treated as cases outside the subcohort (entering just prior to diagnosis, continuing until diagnosis). Because the sampling scheme used in creating the subcohort was stratified, all analyses were stratified by nine age-race groups and each stratum was weighted based on the inverse of its selection probability. We used the method proposed by Prentice (17) to assign weights for calculating the pseudo-likelihood function because it was found to be least biased based on a simulation study. Additional covariates in multivariable regression models included body mass index (BMI), history of diabetes, family history of prostate cancer, and SELECT intervention assignment. Results are also age-and race-adjusted, because all models were stratified by raceage groups before being weighted and combined to generate summary statistics. Additional control for total calcium intake and serum cholesterol concentration did not affect results and these are therefore not included in final models. Statistical analyses were performed using SAS Table 1 gives demographic characteristics and other study-related variables in prostate cancer cases and in the subcohort. Almost 41% of cases were ≥65 years old and 14.4% were AfricanAmerican. Due to matching, the age distribution of the subcohort was similar to that of cases and, due to the sampling scheme, the ratio of cases to subcohort members was 1.0:1.6 for Caucasians and 1.0:3.2 for African-Americans. The percentages of total cases that were diagnosed with Gleason 7-10 cancer (33.1% and 31.9%) and the percentages of men who were obese (30.1% and 33.8%) were similar in cases and the subcohort. A substantially larger percentage of cases had a family history of prostate cancer (28.9%) compared to men in the subcohort (14.8%). Table 2 interpretations of dose response are complicated by the imprecision of hazard ratio point estimates. In addition, very few African American men had vitamin D levels that would be classified as high (≥75 nmol/L ) using our criterion, so that if there was a U-shaped association it would be difficult to detect. For all models examined, there were trends for lower risk of Results for the subset of non-African-American men were similar to those of the entire study sample (Table 5) (12); however in the latest publication based on 1260 men there were no associations with total, high-grade or advanced-stage cancer (20) . In the Alpha-Tocopherol Beta-Carotene Prevention Study there was a significant linear increase across quintiles of serum vitamin D (21) , and in the Janus Serum Bank cohort there was a significant linear increase in the risk of advanced disease, but only among men with blood samples collected in summer and autumn months (13) . Other large studies (2) (3) (4) (5) (6) (7) 22) 
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methodological concerns that make interpretation of these studies difficult. One important consideration is that serum vitamin D is an acute phase reactant, whose concentration in the blood is substantially decreased in persons with even moderately elevated concentrations of Creactive protein (27). Thus, if blood is collected either at or following cancer diagnosis, it is likely that the severity of disease is influencing the concentration of vitamin D. This most likely explains the study by Tretli et al (25) and it may also explain the findings reported by Fang et al (26) in which there was an association of vitamin D with increased lethal cancer only among men whose bloods were collected within 5 years of diagnosis. In the study by Shui et al (20) there were strong inverse associations of vitamin D with lethal cancer. In this study and the study by Fang et al (26) the definition of a lethal cancer is one that causes mortality after diagnosis regardless of its stage or grade at time of diagnosis, and it is thus heavily dependent upon competitive mortality and the length of follow-up after diagnosis. The biases due to this approach are difficult to predict, but using prostate cancer death as the study endpoint seems to us a more straightforward approach to testing hypotheses on "lethal" cancer.
Although our analyses of risk within African American men were based on a much larger sample size than in any previous study, the sample size was still modest and must be interpreted cautiously. It is also notable that the distribution of plasma vitamin D among African-American men was skewed far to the left of the distribution among other races, such that quintiles 1-3 in Another limitation is that even though the SELECT study included over 35,000 men, there were still too few cases to support stratified analyses and, in particular, we had to no power to test whether the results given here differed across SELECT treatment arms. Finally, as in all observational studies, it is possible that there is confounding by unknown factors; however we controlled for all known risk factors for prostate cancer making this possibility less likely.
In summary, we found that optimal level of plasma vitamin D for prostate cancer prevention, serum vitamin D are associated both with total mortality and the risks of a broad range of chronic diseases. It is likely that vitamin D supplementation differentially affects the risks of many diseases and the balance of benefit and harm will need to be understood more fully to formulate public health recommendations. Lacking such data, we believe it prudent to recommend that men over age 50 who are using supplemental vitamin D should limit their dose to levels that do not result in plasma concentrations above 70 nmol/L. Vitamin D values adjusted for month of serum sample. 3 Quintiles are calculated based on the distribution among African American cohort. 4 Quintiles are calculated based on the distribution among the entire cohort. 5 
